Skip to content
Clinical Trials – home
FinlandBack to Finland

Clinical trials in Turku – page 14

300 clinical trials in Turku, Finland across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Turku at a glance
300
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

300 trials in Turku

Open in trial search

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium chloride solution 0.9%
  • Sponsor:Pfizer Inc.

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Seqirus UK Limited

Study on the Effects of VHB937 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Coeliac disease

Not recruiting

Study on the Effects of Amlitelimab for Adults with Non-Responsive Celiac Disease

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Turku

What the registry says about research in the country

01 Respiratory Diseases

Comprehensive research focusing on respiratory infections including trials for influenza, RSV, and human metapneumovirus vaccines. Studies evaluate preventive measures for vulnerable populations.

  • Influenza vaccine development
  • RSV prevention in adults and infants
  • Viral respiratory infections

Multiple trials aim to enhance protection against seasonal respiratory illnesses in different age groups.

02 Infectious Diseases

Research centered on preventing and treating various infectious conditions, including studies of meningococcal vaccines and innovative approaches to viral infections.

  • Meningococcal prevention
  • Herpes Zoster vaccination
  • Yellow fever immunity

Studies focus on developing effective vaccination strategies for different age groups and populations.

03 Metabolic Disorders

Innovative trials examining treatments for obesity and diabetes, with particular attention to weight management therapies and metabolic health improvements.

  • Weight management interventions
  • Type 2 diabetes treatments
  • Combined therapeutic approaches

Research emphasizes lifestyle modifications alongside medical interventions.

04 Oncology

Advanced research in cancer treatment, particularly focusing on breast cancer and innovative therapeutic combinations for improved patient outcomes.

  • Breast cancer therapies
  • Leukemia treatments
  • Prostate cancer interventions

Studies evaluate both targeted therapies and combination treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.